NEW YORK (GenomeWeb News) – Sequenom announced after the close of the market on Thursday that revenues spiked 38 percent year over year during the second quarter as the MaterniT21 Plus fetal aneuploidy test continued to see strong adoption.

For the period ended June 30, total revenues came in at $18.3 million, compared to $13.3 million a year ago, but missed the consensus analyst estimate of $19.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.